Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia through our approved product
Feraccru®/Accrufer® Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.
Our approved product is a novel, stable, non-salt based oral therapy for the treatment of iron deficiency and is approved in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. We are currently selecting a commercial partner for the US where the product will be marketed as Accrufer™.
Our product pipeline
PT20 is a novel iron-based phosphate binder, that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease. PT20 has successfully completed one pivotal study and now requires one further pivotal study after which regulatory filings for marketed approval would be expected to follow.
PT30 and PT40
PT30 is a concept that is aimed at developing a hypo-allergenic IV Iron Therapy, whilst PT40 is being developed to be the first generic version of iron sucrose. Both assets are in preclinical development.
If you are interested in working with us to make Feraccru®/Accrufer® and our other pipeline candidates available to as many patients as possible please contact us.